


Catalog #10-4689

Rebastinib

CAS# 1020172-07-9

4-(4-(3-(3-(t-Butyl)-1-(quinoline-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; 4-[4-[(5-tert-Butyl-2-quinolin-6-yl)pyrazol-3-yl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; DCC-2036

Lot # FBS4029



Rebastinib is a potent ABL1 kinase inhibitor ($IC_{50} = 0.8$ nM) that binds to amino acid residues that are used to switch between active and inactive conformations.¹ It inhibits both phosphorylated and unphosphorylated ABL1 as well as gatekeeper mutant T315I ($IC_{50} = 4$ nM). Rebastinib was active against chronic myeloid leukemia Ba/F3 cells expressing BCR-ABL ($IC_{50} = 19$ nM) and BCR-ABL T315I ($IC_{50} = 63$ nM) and most kinase mutants.² Rebastinib has been reported to inhibit the growth and metastasis of xenografted MDA-MB-231 triple-negative breast cancer cells by targeting AXL/MET.³ It has also been shown to be a potent inhibitor of Tie2 kinase ($IC_{50} = 0.63$ nM).⁴ Rebastinib blocked necroptosis *via* inhibition of RIPK1 and RIPK3.⁵

- 1) Chan *et al.* (2011), *Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036*; *Cancer Cell* **19** 556
- 2) Eide *et al.* (2011), *The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL T315I and exhibits a narrow resistance profile*; *Cancer Res.* **71** 3189
- 3) Shen *et al.* (2019), *Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET*; *Int. J. Cancer* **144** 651
- 4) Harney *et al.* (2017), *The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2^{Hi} Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors*; *Mol. Cancer Ther.* **16** 2486
- 5) Piao *et al.* (2023), *The Bcr-Abl inhibitor DCC-2036 inhibits necroptosis and ameliorates osteoarthritis by targeting RIPK1 and RIPK3 kinases*; *Biomed. Pharmacother.* **161** 114528

PHYSICAL DATA

Molecular Weight:	553.60
Molecular Formula:	C ₃₀ H ₂₈ FN ₇ O ₆
Purity:	>98% (HPLC)
	NMR: (Conforms)
Solubility:	DMSO (>25 mg/mL)
Physical Description:	White to off-white solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com